The company launched in 2023 with $90 million in funding from organizations including Johnson & Johnson’s venture capital arm.

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

The deal for Amplitude’s intravascular lithotripsy platform, which closed last week, included $435 million upfront and up to ...

Created by Johns Hopkins University researchers, the early warning system for sepsis aims to help physicians detect the ...

The decision to wind down the operation in Santa Rosa in about two years comes as the medtech giant combines several ...

Investors including Bezos Expeditions and Thiel Bio supported HistoSonics’ expansion plans last year by participating in a ...

BD named Vitor Roque as chief financial officer Thursday, ending the medtech company’s seven-month search for a permanent ...

PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...

CEO Kevin Lobo said the attack had a “big impact” on first-quarter results. However, the company maintained its full-year ...

The new version of Tandem’s Mobi pump would be the diabetes technology company’s first tubeless device. Tandem Diabetes Care ...

With an intravascular lithotripsy platform, Stryker will enter a booming market that has attracted investment from Johnson & Johnson, Boston Scientific and Abbott.

The device joins a portfolio of vascular technologies that generated 9.5% sales growth on a comparable basis in the first ...